Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

DGAP-Adhoc: Fresenius Medical Care AG & Co. KGaA cuts outlook for FY 2022 due to increased headwinds from U.S. labor market situation and global inflation, and withdraws 2025 targets


DGAP-Ad-hoc: Fresenius Medical Care AG & Co. KGaA / Key word(s): Change in Forecast/Preliminary Results
Fresenius Medical Care AG & Co. KGaA cuts outlook for FY 2022 due to increased headwinds from U.S. labor market situation and global inflation, and withdraws 2025 targets

27-Jul-2022 / 22:38 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


In the second quarter Fresenius Medical Care experienced increasing different headwinds that are now expected to negatively impact the Company´s earnings development in the second half of FY 2022 to a significant larger degree than anticipated when giving guidance. Earnings development in particular is anticipated to be affected by increased wage inflation and worsened staff shortages resulting in capacity constraints in North American Health Care Services. Additionally, the worsening of the macroeconomic environment is expected to result in higher inflation and disruptions in supply chain.

Against this backdrop, Fresenius Medical Care now anticipates for FY 2022, in constant currency and before special items, revenue to grow at the low end of the previously guided low to mid-single digit percentage range and now assumes net income (attributable to shareholders of Fresenius Medical Care AG & Co. KGaA) to decline around a high teens percentage range.

Due to uncertainties of the U.S. labor market and macro-economic inflationary environment, which are assumed to be temporary, Fresenius Medical Care withdraws 2025 targets of compounded annual average increases in the mid-single-digit percentage range for revenue and in the high-single-digit percentage range for net income (attributable to shareholders of Fresenius Medical Care AG & Co. KGaA).


Contact:
Dr. Dominik Heger
EVP | Head of Investor Relations, Strategic Development & Communications
[email protected]
P. +49 6172 609 2601

27-Jul-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Fresenius Medical Care AG & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Phone: +49 (0) 6172- 609 2525
Fax: +49 (0) 6172- 609 2301
E-mail: [email protected]
Internet: www.freseniusmedicalcare.com
ISIN: DE0005785802
WKN: 578580
Indices: DAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE, Luxembourg Stock Exchange
EQS News ID: 1407557

 
End of Announcement DGAP News Service

1407557  27-Jul-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1407557&application_name=news&site_id=sharewise

Fresenius Medical Care AG & Co KGaA ST Stock

€39.33
0.280%
The Fresenius Medical Care AG & Co KGaA ST stock is trending slightly upwards today, with an increase of €0.11 (0.280%) compared to yesterday's price.
Currently there is a rather positive sentiment for Fresenius Medical Care AG & Co KGaA ST with 4 Buy predictions and 0 Sell predictions.
With a target price of 50 € there is a positive potential of 27.13% for Fresenius Medical Care AG & Co KGaA ST compared to the current price of 39.33 €.
Like: 0
Share
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments